CytomX Therapeutics (CTMX) EBT (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly EBT came in at -$18.2 million in Q1 2026, down 177.11% YoY from $23.6 million in Q1 2025, and up 31.25% on a QoQ basis from -$26.5 million in Q4 2025.
CytomX Therapeutics (CTMX) EBT (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of EBT data on file, last reported at -$18.2 million in Q1 2026.
- Quarterly EBT fell 177.11% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.9 million (down 240.79% YoY) and the FY2025 annual result came in at -$17.1 million, down 153.38% from the prior year.
- EBT rose to -$18.2 million in Q1 2026, from -$26.5 million in the prior quarter.
- In the past five years, EBT ranged from a high of $23.6 million in Q1 2025 to a low of -$32.0 million in Q1 2022.
- A 5-year average of -$5.8 million and a median of -$3.3 million in 2023 frame the typical range for EBT.
- The widest YoY moves for EBT: up 893.6% in 2024, down 496.41% in 2024.
- Tracing CTMX's EBT over 5 years: stood at -$8.8 million in 2022, then surged by 121.72% to $1.9 million in 2023, then soared by 893.6% to $18.9 million in 2024, then plunged by 239.7% to -$26.5 million in 2025, then surged by 31.25% to -$18.2 million in 2026.
- The last three EBT figures came in at -$18.2 million (Q1 2026), -$26.5 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -20.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.61 Mn |
| Mar 31, 2026 | -18.19 Mn |
| Dec 31, 2025 | -26.46 Mn |
| Sep 30, 2025 | -14.17 Mn |
| Jun 30, 2025 | -91,000.00 |
| Mar 31, 2025 | 23.59 Mn |
| Dec 31, 2024 | 18.94 Mn |
| Sep 30, 2024 | 5.80 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Mar 31, 2024 | 13.84 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 5.82 Mn |
| Jun 30, 2023 | -1.09 Mn |
| Mar 31, 2023 | -3.31 Mn |
| Dec 31, 2022 | -8.78 Mn |
| Sep 30, 2022 | -29.06 Mn |
| Jun 30, 2022 | -29.50 Mn |
| Mar 31, 2022 | -31.98 Mn |
| Dec 31, 2021 | -34.82 Mn |
| Sep 30, 2021 | -30.98 Mn |